The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish 177Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.

Additional Metadata
Keywords Gastroenteropancreatic neuroendocrine tumour, Neuroendocrine tumour, Peptide receptor radionuclide therapy, Radiolabelled somatostatin analogues
Persistent URL dx.doi.org/10.1159/000475526, hdl.handle.net/1765/108677
Journal Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships
Citation
Hicks, R.J. (Rodney J.), Kwekkeboom, D.J, Krenning, E.P, Bodei, L. (Lisa), Grozinsky-Glasberg, S. (Simona), Arnold, R. (Rudolf), … Ramage, J. (2017). ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues. In Neuroendocrinology: international journal for basic and clinical studies on neuroendocrine relationships (Vol. 105, pp. 295–309). doi:10.1159/000475526